CN114832076A - 一种细小病毒引起猫狗病状的药剂治疗配方 - Google Patents
一种细小病毒引起猫狗病状的药剂治疗配方 Download PDFInfo
- Publication number
- CN114832076A CN114832076A CN202110136280.9A CN202110136280A CN114832076A CN 114832076 A CN114832076 A CN 114832076A CN 202110136280 A CN202110136280 A CN 202110136280A CN 114832076 A CN114832076 A CN 114832076A
- Authority
- CN
- China
- Prior art keywords
- parts
- cats
- ethanol
- dogs
- parvovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 241000282472 Canis lupus familiaris Species 0.000 title claims abstract description 29
- 241000282326 Felis catus Species 0.000 title claims abstract description 29
- 241000125945 Protoparvovirus Species 0.000 title claims abstract description 20
- 208000024891 symptom Diseases 0.000 title claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 72
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 51
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 claims abstract description 46
- QBDCOUHKEVYWLO-UHFFFAOYSA-N Decanoyl acetaldehyde Chemical compound CCCCCCCCCC(=O)CC=O QBDCOUHKEVYWLO-UHFFFAOYSA-N 0.000 claims abstract description 30
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 claims abstract description 25
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 claims abstract description 25
- GSFDOOHGKOHDEL-UHFFFAOYSA-N Dalpanitin Natural products COc1cc(ccc1O)C2=COc3c(C4OC(CO)C(O)C(O)C4O)c(O)cc(O)c3C2=O GSFDOOHGKOHDEL-UHFFFAOYSA-N 0.000 claims abstract description 23
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 23
- SVHDRHWULLNMQC-UHFFFAOYSA-N scoparone Natural products C1=CC(=O)OC2=C1C=C(C(=O)C)C(C(C)=O)=C2 SVHDRHWULLNMQC-UHFFFAOYSA-N 0.000 claims abstract description 23
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 17
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 claims abstract description 17
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 claims abstract description 17
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 claims abstract description 17
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 claims abstract description 17
- DUAGQYUORDTXOR-GPQRQXLASA-N Gentiopicrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)C2=CCOC(=O)C2=CO1 DUAGQYUORDTXOR-GPQRQXLASA-N 0.000 claims abstract description 17
- DUAGQYUORDTXOR-WULZUDSJSA-N Gentiopicrin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)C=2C(C(=O)OCC=2)=CO1 DUAGQYUORDTXOR-WULZUDSJSA-N 0.000 claims abstract description 17
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims abstract description 17
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 claims abstract description 17
- 229940043350 citral Drugs 0.000 claims abstract description 17
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims abstract description 17
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 claims abstract description 17
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 claims abstract description 17
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 claims abstract description 17
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 claims abstract description 17
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 claims abstract description 17
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 17
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000001685 glycyrrhizic acid Substances 0.000 claims abstract description 17
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 17
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 17
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 claims abstract description 17
- 235000011576 oleuropein Nutrition 0.000 claims abstract description 17
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 claims abstract description 17
- 241000131458 Elsholtzia Species 0.000 claims abstract description 16
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 16
- 235000004347 Perilla Nutrition 0.000 claims abstract description 16
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940116229 borneol Drugs 0.000 claims abstract description 15
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 15
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 15
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims abstract description 10
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims abstract description 10
- 241001529821 Agastache Species 0.000 claims abstract description 4
- 241001162994 Rugosus Species 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000013078 crystal Substances 0.000 claims description 16
- 241000125175 Angelica Species 0.000 claims description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 15
- 241000229722 Perilla <angiosperm> Species 0.000 claims description 15
- 238000009835 boiling Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- 240000002505 Pogostemon cablin Species 0.000 claims description 13
- 235000011751 Pogostemon cablin Nutrition 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 10
- 239000012452 mother liquor Substances 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 210000002421 cell wall Anatomy 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 239000011521 glass Substances 0.000 claims description 5
- 239000002655 kraft paper Substances 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 5
- 244000118350 Andrographis paniculata Species 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000007670 refining Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 3
- 241000606768 Haemophilus influenzae Species 0.000 claims description 3
- 229930182555 Penicillin Natural products 0.000 claims description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- KPQJOKRSYYJJEL-VLQRKCJKSA-K [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O Chemical compound [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O KPQJOKRSYYJJEL-VLQRKCJKSA-K 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 235000011477 liquorice Nutrition 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 229940049954 penicillin Drugs 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- CCXAYLQLOLXXKE-DWJAGBRCSA-K trisodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-t Chemical compound [Na+].[Na+].[Na+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C([O-])=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O CCXAYLQLOLXXKE-DWJAGBRCSA-K 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims 7
- 241000382455 Angelica sinensis Species 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000009630 liquid culture Methods 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 6
- 230000009385 viral infection Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 244000124853 Perilla frutescens Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 235000014103 egg white Nutrition 0.000 description 3
- 210000000969 egg white Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 230000007547 defect Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000004916 vomit Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000009447 viral pathogenesis Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/11—Preparation or pretreatment of starting material involving culturing conditions, e.g. cultivation in the dark or under defined water stress
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种细小病毒引起猫狗病状的药剂治疗配方,该药剂治疗配方由以下重量份计的各组分组成:1‑3份滨蒿内酯、0.2‑3份虫草素、1‑5份苍术、0.5‑2份艾叶、2‑3份白芷、0.2‑8份去氧五味子素、0.5‑6份非离子表面活性剂、20‑30份甘油、0.1‑1份冰片、2‑5份乙醇、0.01‑2份鱼腥草素、0.5‑1份芝麻素、2‑5份柠檬醛、0.6‑2份龙胆苦苷、0.05‑1份当归、2‑6份香薷、0.02‑1份苏叶、0.03‑2份穿心莲内酯、0.2‑1份广藿香、0.3‑1份山奈、0.01‑3份甘草酸、2‑6份橄榄苦苷。该细小病毒引起猫狗病状的药剂治疗配方,采用中成药制成,对猫狗动物产生的副作用小,同时可以对多种病毒进行杀毒,也可以对病毒进行防护,减少猫狗动物病毒感染概率。
Description
技术领域
本发明涉及药剂配方技术领域,具体为一种细小病毒引起猫狗病状的药剂治疗配方。
背景技术
病毒是一种个体微小,结构简单,只含一种核酸(DNA或RNA),必须在活细胞内寄生并以复制方式增殖的非细胞型生物。
病毒是一种非细胞生命形态,它由一个核酸长链和蛋白质外壳构成,病毒没有自己的代谢机构,没有酶系统。因此病毒离开了宿主细胞,就成了没有任何生命活动、也不能独立自我繁殖的化学物质。它的复制、转录、和转译的能力都是在宿主细胞中进行,当它进入宿主细胞后,它就可以利用细胞中的物质和能量完成生命活动,按照它自己的核酸所包含的遗传信息产生和它一样的新一代病毒;
而部分细小病毒会引起猫狗病状,使得病毒通过多种途径侵入猫狗身体,并在易感的宿主细胞中增殖的过程。人类病毒是指能感染人体或对人有致病作用的病毒。病毒感染的实质是病毒与猫狗身体、病毒与易感细胞相互作用的过程。病毒感染常因病毒种类、猫狗身体状态不同产生轻重不一的损伤或病毒性疾病。病毒致病是由侵入宿主、感染细胞开始的,致病作用表现在人整体和细胞两个方面;
为了减少猫狗动物病毒感染,提出一种细小病毒引起猫狗病状的药剂治疗配方。
发明内容
(一)解决的技术问题
针对现有技术的不足,本发明试图克服以上缺陷,因此本发明提供了一种细小病毒引起猫狗病状的药剂治疗配方,该药剂治疗配方采用中成药制成,对猫狗动物产生的副作用小,同时可以对多种病毒进行杀毒,也可以对病毒进行防护,达到减少猫狗动物病毒感染概率的目的。
(二)技术方案
为实现以上目的,本发明通过以下技术方案予以实现:一种细小病毒引起猫狗病状的药剂治疗配方,该药剂治疗配方由以下重量份计的各组分组成:1-3份滨蒿内酯、0.2-3份虫草素、1-5份苍术、0.5-2份艾叶、2-3份白芷、0.2-8份去氧五味子素、0.5-6份非离子表面活性剂、20-30份甘油、0.1-1份冰片、2-5份乙醇、0.01-2份鱼腥草素、0.5-1份芝麻素、2-5份柠檬醛、0.6-2份龙胆苦苷、0.05-1份当归、2-6份香薷、0.02-1份苏叶、0.03-2份穿心莲内酯、0.2-1份广藿香、0.3-1份山奈、0.01-3份甘草酸、2-6份橄榄苦苷。
优选的,该药剂治疗配方由以下重量份计的各组分组成:2份滨蒿内酯、0.8份虫草素、3份苍术、0.8份艾叶、2份白芷、4份去氧五味子素、3份非离子表面活性剂、25份甘油、0.5份冰片、4份乙醇、1份鱼腥草素、0.8份芝麻素、4份柠檬醛、1份龙胆苦苷、0.9份当归、3份香薷、0.5份苏叶、1.5份穿心莲内酯、0.7份广藿香、0.8份山奈、1.5份甘草酸、3份橄榄苦苷。
优选的,该药剂治疗配方由以下重量份计的各组分组成:1.5份滨蒿内酯、2份虫草素、3份苍术、0.8份艾叶、2.5份白芷、4份去氧五味子素、3份非离子表面活性剂、22份甘油、0.8份冰片、3份乙醇、0.9份鱼腥草素、0.8份芝麻素、3份柠檬醛、1份龙胆苦苷、0.5份当归、3份香薷、0.7份苏叶、0.8份穿心莲内酯、1份广藿香、1份山奈、3份甘草酸、6份橄榄苦苷。
优选的,所述滨蒿内酯的熔点145-146℃,且其易溶于乙醇、丙酮、氯仿,难溶于水,不溶于石油醚。
优选的,所述鱼腥草素对金黄色葡萄球菌及其耐青霉素株之MIC为62.5-79mg/ml,对流感杆菌为1.28mg/ml,普科氏液体培养基上对结核杆菌H37RV株为15mg/ml。
优选的,在甘草提取的过程中,得到甘草酸铵溶解在含有讲学算量碳酸钠的水溶液中,减压浓缩即得甘草酸二钠、甘草酸三钠。
优选的,该药剂治疗配方的制备方法包括以下步骤:
步骤一、将1L蒸馏水放入锅中烧开后,依次加入乙醇、鱼腥草素、芝麻素、柠檬醛、龙胆苦苷、当归、香薷、苏叶、穿心莲内酯、广藿香、山奈、甘草酸、橄榄苦苷,等水再次烧开后,自然冷却至30℃分装入2升的广口玻璃瓶中,接入甘油,牛皮纸封口后30℃静置培养15天用作菌种母液;
步骤二、先将苍术、艾叶、白芷、去氧五味子素、非离子表面活性剂、冰片混合,然后喷洒重量为上述重量50-100%的菌种母液,50-60℃干燥8-12小时,制成药粉;
步骤三、将滨蒿内酯、虫草素、加入水溶液中煮沸,过滤获得提取液;
步骤四、将提取液与药粉混合,烘干50-60min,随后将中药材粗粉依次进行进行低温微波处理和紫外线辐射处理对中药材粗粉的细胞壁进行脆化处理,最后超微粉碎,得到中药破壁饮片。
优选的,所述穿心莲内酯的制备包括以下步骤:
步骤一、穿心莲叶用95%乙醇浸泡,所得乙醇浸泡取液用活性炭脱色,脱色液蒸馏回收乙醇后的浓缩液静置得到粗晶品;
步骤二、粗晶加15倍量95%乙醇加热溶解,活性炭脱色,趁热过滤,静置重结晶,得淡黄色重结晶品,再经蒸馏水、氯仿、甲醇洗涤精制得到穿心莲内酯成品。
(三)有益效果
本发明提供的一种细小病毒引起猫狗病状的药剂治疗配方。具备以下有益效果:该细小病毒引起猫狗病状的药剂治疗配方,采用中成药制成,对猫狗动物产生的副作用小,同时可以对多种病毒进行杀毒,也可以对病毒进行防护,减少猫狗动物病毒感染概率。
具体实施方式
根据本发明的第一方面,本发明提供一种细小病毒引起猫狗病状的药剂治疗配方,该药剂治疗配方由以下重量份计的各组分组成:1-3份滨蒿内酯、0.2-3份虫草素、1-5份苍术、0.5-2份艾叶、2-3份白芷、0.2-8份去氧五味子素、0.5-6份非离子表面活性剂、20-30份甘油、0.1-1份冰片、2-5份乙醇、0.01-2份鱼腥草素、0.5-1份芝麻素、2-5份柠檬醛、0.6-2份龙胆苦苷、0.05-1份当归、2-6份香薷、0.02-1份苏叶、0.03-2份穿心莲内酯、0.2-1份广藿香、0.3-1份山奈、0.01-3份甘草酸、2-6份橄榄苦苷。
该药剂治疗配方由以下重量份计的各组分组成:2份滨蒿内酯、0.8份虫草素、3份苍术、0.8份艾叶、2份白芷、4份去氧五味子素、3份非离子表面活性剂、25份甘油、0.5份冰片、4份乙醇、1份鱼腥草素、0.8份芝麻素、4份柠檬醛、1份龙胆苦苷、0.9份当归、3份香薷、0.5份苏叶、1.5份穿心莲内酯、0.7份广藿香、0.8份山奈、1.5份甘草酸、3份橄榄苦苷。
该药剂治疗配方由以下重量份计的各组分组成:1.5份滨蒿内酯、2份虫草素、3份苍术、0.8份艾叶、2.5份白芷、4份去氧五味子素、3份非离子表面活性剂、22份甘油、0.8份冰片、3份乙醇、0.9份鱼腥草素、0.8份芝麻素、3份柠檬醛、1份龙胆苦苷、0.5份当归、3份香薷、0.7份苏叶、0.8份穿心莲内酯、1份广藿香、1份山奈、3份甘草酸、6份橄榄苦苷。
滨蒿内酯的熔点145-146℃,且其易溶于乙醇、丙酮、氯仿,难溶于水,不溶于石油醚。
鱼腥草素对金黄色葡萄球菌及其耐青霉素株之MIC为62.5-79mg/ml,对流感杆菌为1.28mg/ml,普科氏液体培养基上对结核杆菌H37RV株为15mg/ml。
在甘草提取的过程中,得到甘草酸铵溶解在含有讲学算量碳酸钠的水溶液中,减压浓缩即得甘草酸二钠、甘草酸三钠。
该药剂治疗配方的制备方法包括以下步骤:
步骤一、将1L蒸馏水放入锅中烧开后,依次加入乙醇、鱼腥草素、芝麻素、柠檬醛、龙胆苦苷、当归、香薷、苏叶、穿心莲内酯、广藿香、山奈、甘草酸、橄榄苦苷,等水再次烧开后,自然冷却至30℃分装入2升的广口玻璃瓶中,接入甘油,牛皮纸封口后30℃静置培养15天用作菌种母液;
步骤二、先将苍术、艾叶、白芷、去氧五味子素、非离子表面活性剂、冰片混合,然后喷洒重量为上述重量50-100%的菌种母液,50-60℃干燥8-12小时,制成药粉;
步骤三、将滨蒿内酯、虫草素、加入水溶液中煮沸,过滤获得提取液;
步骤四、将提取液与药粉混合,烘干50-60min,随后将中药材粗粉依次进行进行低温微波处理和紫外线辐射处理对中药材粗粉的细胞壁进行脆化处理,最后超微粉碎,得到中药破壁饮片。
穿心莲内酯的制备包括以下步骤:
步骤一、穿心莲叶用95%乙醇浸泡,所得乙醇浸泡取液用活性炭脱色,脱色液蒸馏回收乙醇后的浓缩液静置得到粗晶品;
步骤二、粗晶加15倍量95%乙醇加热溶解,活性炭脱色,趁热过滤,静置重结晶,得淡黄色重结晶品,再经蒸馏水、氯仿、甲醇洗涤精制得到穿心莲内酯成品。
实施例1
该药剂治疗配方由以下重量份计的各组分组成:2份滨蒿内酯、0.8份虫草素、3份苍术、0.8份艾叶、2份白芷、4份去氧五味子素、3份非离子表面活性剂、25份甘油、0.5份冰片、4份乙醇、1份鱼腥草素、0.8份芝麻素、4份柠檬醛、1份龙胆苦苷、0.9份当归、3份香薷、0.5份苏叶、1.5份穿心莲内酯、0.7份广藿香、0.8份山奈、1.5份甘草酸、3份橄榄苦苷。
实施例2
该药剂治疗配方由以下重量份计的各组分组成:1.5份滨蒿内酯、2份虫草素、3份苍术、0.8份艾叶、2.5份白芷、4份去氧五味子素、3份非离子表面活性剂、22份甘油、0.8份冰片、3份乙醇、0.9份鱼腥草素、0.8份芝麻素、3份柠檬醛、1份龙胆苦苷、0.5份当归、3份香薷、0.7份苏叶、0.8份
穿心莲内酯、1份广藿香、1份山奈、3份甘草酸、6份橄榄苦苷。
实施例3
该药剂治疗配方的制备方法时,首先将1L蒸馏水放入锅中烧开后,依次加入乙醇、鱼腥草素、芝麻素、柠檬醛、龙胆苦苷、当归、香薷、苏叶、穿心莲内酯、广藿香、山奈、甘草酸、橄榄苦苷,等水再次烧开后,自然冷却至30℃分装入2升的广口玻璃瓶中,接入甘油,牛皮纸封口后30℃静置培养15天用作菌种母液;先将苍术、艾叶、白芷、去氧五味子素、非离子表面活性剂、冰片混合,然后喷洒重量为上述重量60%的菌种母液,50℃干燥8小时,制成药粉;将滨蒿内酯、虫草素、加入水溶液中煮沸,过滤获得提取液;将提取液与药粉混合,烘干50min,随后将中药材粗粉依次进行进行低温微波处理和紫外线辐射处理对中药材粗粉的细胞壁进行脆化处理,最后超微粉碎,得到中药破壁饮片。
通过试验,准备小鼠四只,鸡蛋清溶液,注射器,棉线,直尺,小鼠固定器,生理盐水,通过本方法制备的中药破壁饮片。
将小鼠分为两组,分别测量膝关节的周长。(后因膝关节效果不明显尝试用尾巴根部和大腿肌肉,最后选用大腿肌肉注射测量周长方案。)
给实验组小鼠大腿肌肉液注射鸡蛋清溶液0.2ml/只,水对照组注射生理盐水0.2ml/只。(三十分钟后,实验组小鼠大腿周长未有明显变化,估计是因为免疫反应激活时间相对较长,鸡蛋清溶液浓度不够或者剂量太少,未达到液观察急性炎症的实验目的,后选用隔壁组药品二甲苯改进实验。先将四只小鼠腿部每只注射通过本方法制备的中药破壁饮片溶液0.2ml溶液按照生理盐水:通过本方法制备的中药破壁饮片9:1比例配置,以缓解二甲苯强烈的刺激作用引起小鼠应激反应。然后将实验组小鼠每只大腿注射0.1ml二甲苯,对照组每只同一位置注射0.1ml生理盐水)
三十分钟后测量每只小鼠大腿周长,再每只尾部静脉注射通过本方法制备的中药破壁饮片0.5ml。(可能是因为缓释片溶解度太小20分钟后未有明显现象,改用隔壁组药品地塞米松,再次测量周长后,每只尾静脉注射地塞米松,0.3ml);
经过检测,该中药破壁饮片病毒杀灭率达到95%。
实施例4
该药剂治疗配方的制备方法时,将1L蒸馏水放入锅中烧开后,依次加入乙醇、鱼腥草素、芝麻素、柠檬醛、龙胆苦苷、当归、香薷、苏叶、穿心莲内酯、广藿香、山奈、甘草酸、橄榄苦苷,等水再次烧开后,自然冷却至30℃分装入2升的广口玻璃瓶中,接入甘油,牛皮纸封口后30℃静置培养15天用作菌种母液;先将苍术、艾叶、白芷、去氧五味子素、非离子表面活性剂、冰片混合,然后喷洒重量为上述重量80%的菌种母液,55℃干燥10小时,制成药粉;将滨蒿内酯、虫草素、加入水溶液中煮沸,过滤获得提取液;将提取液与药粉混合,烘干55min,随后将中药材粗粉依次进行进行低温微波处理和紫外线辐射处理对中药材粗粉的细胞壁进行脆化处理,最后超微粉碎,得到中药破壁饮片。
实施例5
该穿心莲内酯制备时,首先将穿心莲叶用95%乙醇浸泡,所得乙醇浸泡取液用活性炭脱色,脱色液蒸馏回收乙醇后的浓缩液静置得到粗晶品;然后粗晶加15倍量95%乙醇加热溶解,活性炭脱色,趁热过滤,静置重结晶,得淡黄色重结晶品,再经蒸馏水、氯仿、甲醇洗涤精制得到穿心莲内酯成品。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (8)
1.一种细小病毒引起猫狗病状的药剂治疗配方,其特征在于,该药剂治疗配方由以下重量份计的各组分组成:1-3份滨蒿内酯、0.2-3份虫草素、1-5份苍术、0.5-2份艾叶、2-3份白芷、0.2-8份去氧五味子素、0.5-6份非离子表面活性剂、20-30份甘油、0.1-1份冰片、2-5份乙醇、0.01-2份鱼腥草素、0.5-1份芝麻素、2-5份柠檬醛、0.6-2份龙胆苦苷、0.05-1份当归、2-6份香薷、0.02-1份苏叶、0.03-2份穿心莲内酯、0.2-1份广藿香、0.3-1份山奈、0.01-3份甘草酸、2-6份橄榄苦苷。
2.根据权利要求1所述的细小病毒引起猫狗病状的药剂治疗配方,其特征在于:该药剂治疗配方由以下重量份计的各组分组成:2份滨蒿内酯、0.8份虫草素、3份苍术、0.8份艾叶、2份白芷、4份去氧五味子素、3份非离子表面活性剂、25份甘油、0.5份冰片、4份乙醇、1份鱼腥草素、0.8份芝麻素、4份柠檬醛、1份龙胆苦苷、0.9份当归、3份香薷、0.5份苏叶、1.5份穿心莲内酯、0.7份广藿香、0.8份山奈、1.5份甘草酸、3份橄榄苦苷。
3.根据权利要求1所述的细小病毒引起猫狗病状的药剂治疗配方,其特征在于:该药剂治疗配方由以下重量份计的各组分组成:1.5份滨蒿内酯、2份虫草素、3份苍术、0.8份艾叶、2.5份白芷、4份去氧五味子素、3份非离子表面活性剂、22份甘油、0.8份冰片、3份乙醇、0.9份鱼腥草素、0.8份芝麻素、3份柠檬醛、1份龙胆苦苷、0.5份当归、3份香薷、0.7份苏叶、0.8份穿心莲内酯、1份广藿香、1份山奈、3份甘草酸、6份橄榄苦苷。
4.根据权利要求1所述的细小病毒引起猫狗病状的药剂治疗配方,其特征在于:所述滨蒿内酯的熔点145-146℃,且其易溶于乙醇、丙酮、氯仿,难溶于水,不溶于石油醚。
5.根据权利要求1所述的细小病毒引起猫狗病状的药剂治疗配方,其特征在于:所述鱼腥草素对金黄色葡萄球菌及其耐青霉素株之MIC为62.5-79mg/ml,对流感杆菌为1.28mg/ml,普科氏液体培养基上对结核杆菌H37RV株为15mg/ml。
6.根据权利要求1所述的细小病毒引起猫狗病状的药剂治疗配方,其特征在于:在甘草提取的过程中,得到甘草酸铵溶解在含有讲学算量碳酸钠的水溶液中,减压浓缩即得甘草酸二钠、甘草酸三钠。
7.根据权利要求1所述的细小病毒引起猫狗病状的药剂治疗配方,其特征在于:该药剂治疗配方的制备方法包括以下步骤:
步骤一、将1L蒸馏水放入锅中烧开后,依次加入乙醇、鱼腥草素、芝麻素、柠檬醛、龙胆苦苷、当归、香薷、苏叶、穿心莲内酯、广藿香、山奈、甘草酸、橄榄苦苷,等水再次烧开后,自然冷却至30℃分装入2升的广口玻璃瓶中,接入甘油,牛皮纸封口后30℃静置培养15天用作菌种母液;
步骤二、先将苍术、艾叶、白芷、去氧五味子素、非离子表面活性剂、冰片混合,然后喷洒重量为上述重量50-100%的菌种母液,50-60℃干燥8-12小时,制成药粉;
步骤三、将滨蒿内酯、虫草素、加入水溶液中煮沸,过滤获得提取液;
步骤四、将提取液与药粉混合,烘干50-60min,随后将中药材粗粉依次进行进行低温微波处理和紫外线辐射处理对中药材粗粉的细胞壁进行脆化处理,最后超微粉碎,得到中药破壁饮片。
8.根据权利要求1所述的细小病毒引起猫狗病状的药剂治疗配方,其特征在于:所述穿心莲内酯的制备包括以下步骤:
步骤一、穿心莲叶用95%乙醇浸泡,所得乙醇浸泡取液用活性炭脱色,脱色液蒸馏回收乙醇后的浓缩液静置得到粗晶品;
步骤二、粗晶加15倍量95%乙醇加热溶解,活性炭脱色,趁热过滤,静置重结晶,得淡黄色重结晶品,再经蒸馏水、氯仿、甲醇洗涤精制得到穿心莲内酯成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110136280.9A CN114832076A (zh) | 2021-02-01 | 2021-02-01 | 一种细小病毒引起猫狗病状的药剂治疗配方 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110136280.9A CN114832076A (zh) | 2021-02-01 | 2021-02-01 | 一种细小病毒引起猫狗病状的药剂治疗配方 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114832076A true CN114832076A (zh) | 2022-08-02 |
Family
ID=82560679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110136280.9A Pending CN114832076A (zh) | 2021-02-01 | 2021-02-01 | 一种细小病毒引起猫狗病状的药剂治疗配方 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114832076A (zh) |
-
2021
- 2021-02-01 CN CN202110136280.9A patent/CN114832076A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112057546A (zh) | 一种蜂胶灵芝孢子粉组合物及其制备方法和应用 | |
CN102895326B (zh) | 一种治疗小儿感冒的中药组合物及其制备方法 | |
CN109045035B (zh) | 7-(2,2-二甲基-3-丁烯酰胺基)-八氢苯喹啉乙酸酯在制备治疗肝病药物的应用 | |
CN101698011B (zh) | 治疗畜禽流行性腹泻的药物 | |
CN100586454C (zh) | 一种禽用中药组合物及其制备方法和应用 | |
CN101417018A (zh) | 一种具有清热解毒、凉血止痢功能的兽用注射剂的制备方法 | |
CN104474219A (zh) | 治疗真菌引起的甲鱼水霉病的药物 | |
CN114832076A (zh) | 一种细小病毒引起猫狗病状的药剂治疗配方 | |
CN103040931A (zh) | 一种治疗哺乳动物子宫内膜炎的中药制剂 | |
CN101664432A (zh) | 黄芪的微生物发酵制剂的制备方法 | |
CN101314016B (zh) | 用于治疗猪高热症的复方穿心莲注射液及其制备方法 | |
CN102973558A (zh) | 苦参碱在制备抗流感病毒药物中的应用 | |
CN103784685B (zh) | 治疗畜禽病毒性传染病的中药组合物及其制备方法和应用 | |
CN1135979C (zh) | 槐果碱作为制备柯萨奇b病毒性心肌炎病因治疗药物的用途及其制法 | |
CN101358222A (zh) | 一种以蕨麻为原料微波辅助提取抗辐射多糖的方法 | |
CN101966245B (zh) | 一种治疗畜禽病毒性疾病的复方注射液及其制备方法 | |
CN110314219A (zh) | 一种用于糖尿病并发症的喷剂 | |
CN102631360A (zh) | 齐墩果烷型皂苷在制备治疗和/或预防血吸虫病药物中的应用 | |
CN116650577B (zh) | 一种锦灯笼提取物在抗鸡传染性支气管炎病毒中的应用 | |
CN107669957B (zh) | 一种防治动物包虫病的复方中药提取物及其应用 | |
CN104208136A (zh) | 苦豆子碱奶牛乳房注入剂的制备工艺和使用方法 | |
CN118078791A (zh) | 丁香酸的新用途 | |
CN101229209A (zh) | 水飞蓟油脂质体的制备方法及应用 | |
CN104547019A (zh) | 一种治疗猪腹泻的中药穴位缓释注射液 | |
CN104491043A (zh) | 治疗牛气胀的中草药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |